Home 2018-05-18T12:50:50+00:00

We are building a community of thought-leaders to help solve one of the most amazing riddles in modern medical history: how to unlock the universe of cannabinoid wellness properties from the cannabis plant.

More than 90% of cannabinoids are non-euphoric and most all of them have therapeutic benefit.  What’s more, they interact with our ECS in ways that are beginning to reshape our understanding of health and wellness.

The endocannabinoid system (ECS) is the one of the most ubiquitous networks of receptors in the human body; It’s a retrograde signaling system helping to homeostaticly regulate neurotransmission. 

Science is teaching us that by targeting the right receptors with the right cannabinoids, a multitude of wellness indications, applications, and potentially groundbreaking medical breakthroughs are not only plausible—but probable.

This is healthcare disruption.  And it’s happening.

We believe the cannabis industry is in the nascent stages of a multi-year and efficacy-led secular bull market.   Aggressive global adoption has provided opportunities in Israel, Canada, Europe, Australia, and the United States. 

We view the cannabis spectrum through the lens of ten verticals that include biopharmaceuticals, industrial hemp & farming, extraction & nutraceuticals, compliant laboratories, cultivation & dispensaries, cosmetics & vanity, and pet foods & supplements.

CB1 Capital does not touch the plant or move the plant across state lines; we buy, sell, and invest in securities of publicly traded companies only.

Get updates on the latest cannabis related news directly in your e-mail in our Morning Update newsletter.
 
* indicates required
 
LEARN MORE

TODD HARRISON

Todd Harrison is the Founding Partner of CB1 and our Chief Investment Officer. Todd has spent almost three decades on Wall Street managing risk and researching market strategies. His institutional experience includes Morgan Stanley Global Equity Derivatives (VP), The Galleon Group (MD-Derivatives), and Cramer, Berkowitz LLC (President and Head of Trading).

Mr. Harrison was also the Founder and CEO of Minyanville Media, Inc., an Emmy Award winning financial media company.

TODD HARRISON

Todd Harrison is the Founding Partner of CB1 and our Chief Investment Officer. Todd has spent almost three decades on Wall Street managing risk and researching market strategies. His institutional experience includes Morgan Stanley Global Equity Derivatives (VP), The Galleon Group (MD-Derivatives), and Cramer, Berkowitz LLC (President and Head of Trading).

Mr. Harrison also was the Founder and CEO of Minyanville Media, Inc., an Emmy Award winning financial media company.

LOREN DEFALCO

Loren DeFalco is a Partner of CB1 and our Head of Research. He cured himself of epileptic seizures through a regime of CBD and cannabinoids nine years ago and continued to research ECS through medical journals and scientific developments. His understanding of the ECS system and nutraceutical arena makes him an ideal choice to lead our research efforts.

Jon Tyras cb1 capital

JON TYRAS

Jon Tyras is a Partner of CB1 and our Chief Operating Officer, Chief Financial Officer and Chief Compliance Officer. Jon has spent over 20 years in the industry. He was most recently the Chief Financial Officer and General Counsel of the $15 billion public securities platform of Brookfield Asset Management, a leading global alternative asset manager with approximately $250 billion in AUM

RYDER JEANES

Ryder Jeanes is a Vice President at CB1 and handles a wide array of duties from investor relations to portfolio research and analysis.  Ryder has spent the last 15 years in the commercial real estate industry and the last 10 years as an independent equities and options trader.

JOSH FELKER

Josh Felker is a Research Analyst at CB1 and our resident Canadian market reference. He has written extensively for FelkerInvesting.com, reaching the top pages of Reddit/Google for articles regarding the valuation of Canadian Licensed Producers.

OUR ADVISORY BOARD

DR. ETHAN RUSSO

Board Certified Neurologist, psychopharmacology researcher; Director of Research & Development, International Cannabis and Cannabinoid Institute (ICCI), former Senior Medical Advisor, GW Pharmaceuticals; former Medical Director, PHYTECS.

DR. JULIE HOLLAND

Psychiatrist and psychopharmacologist, Author of the bestsellers “Weekends at Bellevue” and “Moody Bitches”, editor of “The Pot Book: A Complete Guide to Cannabis”, medical monitor for a clinical study examining the efficacy of using cannabis in the treatment of Post Traumatic Stress Disorder in veterans.

LORNE GERTNER

Chairman of HG2 Capital Corp, CEO of Hill & Gertner Capital Group; Co-Founder, The Cronos Group; Director, Emblem Corp.; Co-Founder & Chairman Tokyo Smoke; Investment Partner and Director, Green Acre Capital.

GOV. GARY JOHNSON

Twenty-ninth governor of New Mexico, two-time Presidential candidate. Founder, Big J Enterprises; Former CEO of Cannabis Sativa, Inc.

DAVE CHARNICK

Subject Matter Expert, Founder, Kalyx Development Inc. and Special Advisor, Cannabis Benchmarks, a division of New Leaf Data Sciences.

PRESS

SEE MORE PRESS COVERAGE

BLOG

Survive and Thrive

April 16th, 2018|

By Todd Harrison | April 16, 2018 The first quarter of 2018 is in the books, and what a quarter it was. After years of steady stock market gains, volatility exploded across asset classes. I’ve traded through several volatile [...]

Cannabis Going Global

February 25th, 2018|

By Todd Harrison | February 15, 2018 January did not lack for excitement in the cannabinoid-wellness space as volatility arrived early and often. Between the decision by Jeff Sessions to repeal state cannabis protections to the brief-but-tenuous government shutdown, [...]

Land of the Rising Bud

February 10th, 2018|

By Loren DeFalco | February 10, 2018 Japan has long been known as the “Land of the Rising Sun”; however, with an aging population, it may soon become known as the Land of the Rising Bud. Japan’s recent delving [...]

VIEW ALL

SCIENCE

What is the Endocannabinoid System? (ECS)

The Endocannabinoid System is a recently discovered biological system comprised of lipid messengers that has receptors lining the entire body.

Cannabinoids (compounds in the cannabis plant) can act on the ECS as regulators of neuro-transmission flow and homeostatic regulators of inflammation in the body.

There are a wide range of diseases affected by the ECS, including cancer and most inflammatory related diseases.

LEARN MORE
Research Studies By Indication/Ailment

CONTACT CB1 CAPITAL

CB1 Capital

Phone   516.331.2636

Email   Info@CB1Cap.com

Please read important disclosures here